Gilead Sciences (GILD) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY26 Guidance

Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.03, $0.13 better than the analyst estimate of $1.90. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.91 billion.

GUIDANCE:

Gilead Sciences sees FY2026 EPS of ($1.05)-($0.65), versus the consensus of $8.65. Gilead Sciences sees FY2026 revenue of $30-30.4 billion, versus the consensus of $30.2 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• HighPeak Energy mulls sale - Reuters
• US approves $24.3 billion F-35 fighter jet sale to Saudi Arabia
• SpaceX: targeting to launch Starship flight 14 early as Sep 28